UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $627
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $670 to $627.
UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $670 to $627.